Ultra-low dose hormones 'future' of symptom relief in menopause

Owen, Olwen Glynn
July 2008
British Journal of Hospital Medicine (17508460);Jul2008, Vol. 69 Issue 7, p376
Academic Journal
The article reports on ultra-low dose versions of hormone replacement therapy as the best way for relieving menopausal symptoms in Great Britain. According to Dr. David Sturdee, Consultant Gynecologist at Birmingham Heartlands and Solihull Hospitals, the ultra-low dose combinations of 17beta-oestradiol and norethisterone acetate show significant differences from placebo in reducing hot flushes, alleviating sleep problems and achieving amenorrhoea.


Related Articles

  • NEW DOSAGE STRENGTH.  // Drug Topics;7/9/2007, Vol. 151 Issue 13, p42 

    The article evaluates the Activella Tablets estradiol/norethindrone acetate from Novo Nordisk.

  • Influence of the Placebo Effect upon the Healing Process. Squire, Carol // Positive Health;Apr2002, Issue 75, p27 

    Focuses on the influence of placebo effect in the healing process. Dependence of allopathic medicine to the placebo response; Assumption on the therapeutic effects of the placebo; Belief of the patient to the effectivity of a placebo.

  • Ethical questions over clinical use of placebo.  // Australian Journal of Pharmacy;May2009, Vol. 90 Issue 1068, p79 

    The article highlights some ethical questions over the clinical use of placebo treatments.

  • The Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis (POPART'MUS) trial: rationale, objectives and state of advancement.  // Current Medical Literature: Multiple Sclerosis;2010, Vol. 1 Issue 4, p97 

    The article discusses a study by S. Vukusic and colleagues on the prevention of post-partum relapses of multiple sclerosis (MS) with progestin and estradiol-induced therapy. It notes that multiple sclerosis (MS) commonly occurs in young adulthood among females during their child-bearing years....

  • Placebo Therapy and the Law: Prescribe with Care*. Kapp, Marshall B. // American Journal of Law & Medicine;Winter83, Vol. 8 Issue 4, p371 

    The use of placebos by physicians for therapeutic purposes is a common part of clinical medical practice. This Article examines the legal and ethical ramifications of placebo prescription. In particular, ethical concerns are related to substantive legal theories that may be advanced to attack or...

  • Evaluating minimal clinically important differences for the acne-specific quality of life questionnaire. McLeod, Lori D.; Fehnel, Sheri E.; Brandrnan, Jane; Symonds, Tara; Brandman, Jane // PharmacoEconomics;2003, Vol. 21 Issue 15, p1069 

    Background: The Acne-Specific Quality of Life Questionnaire (Acne-QoL) is a responsive, reliable and valid instrument developed to measure the impact of facial acne across four dimensions of patient QOL. Score changes on this instrument have been used to report statistically...

  • No evidence that placebos have powerful clinical effects, study says. Gottlieb, Scott // BMJ: British Medical Journal (International Edition);06/02/2001, Vol. 322 Issue 7298, p1325 

    Reports that treatment with placebo shows no evidence of having powerful clinical effects, according a study conducted at the University of Copenhagen. Reservations by many physicians toward the clinical use of placebos; Details of the study, which tested primarily the clinical effects of...

  • EMA's reflection on placebo does not reflect patients' interests. Bertele', Vittorio; Banzi, Rita; Gluud, Christian; Garattini, Silvio // European Journal of Clinical Pharmacology;May2012, Vol. 68 Issue 5, p877 

    In this article the authors discuss the European Medicine Agency's proposed policy on the extended use of placebo in research trials which evaluate pharmaceuticals. They are critical of the policy and suggest that is not in the best interest of patients and only serve to benefit drug...

  • Is the exclusion of children under 24 months from anthelmintic treatment justifiable? Montresor, Antonio; Stoltzfus, Rebecca J.; Albonico, Marco; Tielsch, James M.; Rice, Amy L.; Chwaya, Hababu M.; Savioli, Lorenzo // Transactions of the Royal Society of Tropical Medicine & Hygiene;Mar2002, Vol. 96 Issue 2, p197 

    There are no reports documenting toxicity or adverse effects after treatment of children aged < 24 months with benzimidazole derivatives and there is an urgent need to clarify this point in light of the potential detrimental effect that soil-transmitted helminthiasis has on this age-group. A...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics